Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Hulstaert

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Journal of Comparative Effectiveness Research|November 4, 2015
The importance of test accuracy in economic evaluations of companion diagnosticsLorena San Miguel, Frank Hulstaert
BMJ Open|November 9, 2014
Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysisMattias Neyt, Frank Hulstaert, Wilfried Gyselaers
Prenatal Diagnosis|October 8, 2015
Contingent non-invasive prenatal testing: an opportunity to improve non-genetic aspects of fetal aneuploidy screeningWilfried Gyselaers, Frank Hulstaert, Mattias Neyt
Frontiers in Pharmacology|October 21, 2011
Valorising and creating access to innovative medicines in the European unionLieven Annemans, Irina Cleemput, Frank Hulstaert, et al.
International Journal of Technology Assessment in Health Care|January 18, 2020
Closing the cycle of innovation in healthcare in EuropeFrank Hulstaert, Alric Ruether, Jacques Demotes, et al.
Journal of Comparative Effectiveness Research|November 19, 2013
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EULieven Annemans, Irina Cleemput, Frank Hulstaert, et al.
Journal of Comparative Effectiveness Research|September 6, 2016
Publicly funded practice-oriented clinical trials: of importance for healthcare payersMattias Neyt, Thierry Christiaens, Jacques Demotes, et al.
Health Policy (Amsterdam, Netherlands)|January 1, 2008
Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for BelgiumMattias Neyt, Michel Huybrechts, Frank Hulstaert, et al.
European Journal of Health Law|December 2, 2011
Market introduction of innovative high risk medical devices: towards a recast of the directive concerning medical devicesImgard Vinck, Frank Hulstaert, Hans Van Brabandt, et al.
Pharmacoeconomics|September 13, 2011
Critical assessment of belgian reimbursement dossiers of orphan drugsAlain Denis, Lut Mergaert, Christel Fostier, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Journal of Comparative Effectiveness Research|November 4, 2015
The importance of test accuracy in economic evaluations of companion diagnosticsLorena San Miguel, Frank Hulstaert
BMJ Open|November 9, 2014
Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysisMattias Neyt, Frank Hulstaert, Wilfried Gyselaers
Prenatal Diagnosis|October 8, 2015
Contingent non-invasive prenatal testing: an opportunity to improve non-genetic aspects of fetal aneuploidy screeningWilfried Gyselaers, Frank Hulstaert, Mattias Neyt
Frontiers in Pharmacology|October 21, 2011
Valorising and creating access to innovative medicines in the European unionLieven Annemans, Irina Cleemput, Frank Hulstaert, et al.
International Journal of Technology Assessment in Health Care|January 18, 2020
Closing the cycle of innovation in healthcare in EuropeFrank Hulstaert, Alric Ruether, Jacques Demotes, et al.
Journal of Comparative Effectiveness Research|November 19, 2013
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EULieven Annemans, Irina Cleemput, Frank Hulstaert, et al.
Journal of Comparative Effectiveness Research|September 6, 2016
Publicly funded practice-oriented clinical trials: of importance for healthcare payersMattias Neyt, Thierry Christiaens, Jacques Demotes, et al.
Health Policy (Amsterdam, Netherlands)|January 1, 2008
Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for BelgiumMattias Neyt, Michel Huybrechts, Frank Hulstaert, et al.
European Journal of Health Law|December 2, 2011
Market introduction of innovative high risk medical devices: towards a recast of the directive concerning medical devicesImgard Vinck, Frank Hulstaert, Hans Van Brabandt, et al.
Pharmacoeconomics|September 13, 2011
Critical assessment of belgian reimbursement dossiers of orphan drugsAlain Denis, Lut Mergaert, Christel Fostier, et al.
Pageof 4